Amber Salter1, Tuula Tyry1, Guoqiao Wang1, Robert J Fox1, Gary Cutter1, Ruth Ann Marrie1. 1. Division of Biostatistics (AS, GW), Washington University in St. Louis, MO; Division of Neurology (TT), Dignity Health, St. Joseph's Hospital and Medical Center, Phoenix, AZ; Department of Neurology and Neurological Institute (RJF), Cleveland Clinic, OH; Department of Biostatistics (GC), University of Alabama at Birmingham; and Departments of Internal Medicine and Community Health Sciences (RAM), University of Manitoba, Winnipeg, Canada.
Abstract
BACKGROUND: In multiple sclerosis (MS), comorbidities have been associated with disability progression and an increased risk of mortality. We investigated the association between comorbidities and mortality in MS after accounting for disability and health behaviors. METHODS: We followed North American Research Committee on Multiple Sclerosis (NARCOMS) Registry participants who completed the Fall 2006 survey on comorbidities until death (reported or matched in the National Death Index) or date of last follow-up in 2014. We used proportional hazards regression to investigate the association between comorbidities and mortality, controlling for demographic, clinical, health behavior, and disability factors. RESULTS: Of 9,496 participants meeting the inclusion criteria, 502 (5.3%) were deceased. Most participants reported having ≤3 comorbid conditions (70.9% survivors, 76.9% decedents). In individual regression models, vascular, visual, and mental comorbidities were associated with increased mortality risk after adjustment for factors associated with survival. When combined into a single model, vascular (hazard ratio 1.269; 1.041-1.547), visual (1.490; 1.199-1.852), and mental comorbidities (excluding anxiety, 1.239; 1.024-1.499) remained independently associated with an increased risk of mortality. CONCLUSIONS: Presence of comorbidities was independently associated with an increased risk of mortality as compared to absence of comorbidities after adjusting for factors associated with survival. Specifically, vascular, visual, and mental comorbidities increased the risk of mortality. This highlights the need for clinicians to attend to these comorbidities, which can be modified by treatments or other interventions, and potentially reduce the risk of mortality in persons with MS who have these conditions.
BACKGROUND: In multiple sclerosis (MS), comorbidities have been associated with disability progression and an increased risk of mortality. We investigated the association between comorbidities and mortality in MS after accounting for disability and health behaviors. METHODS: We followed North American Research Committee on Multiple Sclerosis (NARCOMS) Registry participants who completed the Fall 2006 survey on comorbidities until death (reported or matched in the National Death Index) or date of last follow-up in 2014. We used proportional hazards regression to investigate the association between comorbidities and mortality, controlling for demographic, clinical, health behavior, and disability factors. RESULTS: Of 9,496 participants meeting the inclusion criteria, 502 (5.3%) were deceased. Most participants reported having ≤3 comorbid conditions (70.9% survivors, 76.9% decedents). In individual regression models, vascular, visual, and mental comorbidities were associated with increased mortality risk after adjustment for factors associated with survival. When combined into a single model, vascular (hazard ratio 1.269; 1.041-1.547), visual (1.490; 1.199-1.852), and mental comorbidities (excluding anxiety, 1.239; 1.024-1.499) remained independently associated with an increased risk of mortality. CONCLUSIONS: Presence of comorbidities was independently associated with an increased risk of mortality as compared to absence of comorbidities after adjusting for factors associated with survival. Specifically, vascular, visual, and mental comorbidities increased the risk of mortality. This highlights the need for clinicians to attend to these comorbidities, which can be modified by treatments or other interventions, and potentially reduce the risk of mortality in persons with MS who have these conditions.
Authors: Ali Manouchehrinia; Mikail Weston; Christopher R Tench; John Britton; Cris S Constantinescu Journal: J Neurol Neurosurg Psychiatry Date: 2014-02-25 Impact factor: 10.154
Authors: M Moccia; R Lanzillo; R Palladino; G T Maniscalco; A De Rosa; C Russo; M Massarelli; A Carotenuto; E Postiglione; O Caporale; M Triassi; V Brescia Morra Journal: Eur J Neurol Date: 2015-04-27 Impact factor: 6.089
Authors: Gary R Cutter; Jeffrey Zimmerman; Amber R Salter; Volker Knappertz; Gustavo Suarez; John Waterbor; Virginia J Howard; Ruth Ann Marrie Journal: Mult Scler Relat Disord Date: 2015-07-18 Impact factor: 4.339
Authors: Douglas S Goodin; George C Ebers; Gary Cutter; Stuart D Cook; Timothy O'Donnell; Anthony T Reder; Marcelo Kremenchutzky; Joel Oger; Mark Rametta; Karola Beckmann; Volker Knappertz Journal: BMJ Open Date: 2012-11-30 Impact factor: 2.692
Authors: Lara Marie Pangan Lo; Bruce V Taylor; Tania Winzenberg; Andrew J Palmer; Leigh Blizzard; Ingrid van der Mei Journal: J Neurol Date: 2020-09-03 Impact factor: 4.849
Authors: Julia O'Mahony; Amber Salter; Beyza Ciftci; Robert J Fox; Gary R Cutter; Ruth Ann Marrie Journal: Neurology Date: 2022-08-10 Impact factor: 11.800